FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD


January 11, 2018

In This Article

Parsabiv (etelcalcetide)


Secondary hyperparathyroidism in adults with chronic kidney disease (CKD) on hemodialysis


Binds to the calcium-sensing receptor (CaSR) and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.


5 mg IV bolus injection 3 times per week at the end of hemodialysis treatment. Individualize and determine maintenance dose by titration based on parathyroid hormone (PTH) and corrected serum calcium response. Dosage range: 2.5-15 mg IV 3 times per week.


Approval was based on a study that compared etelcalcetide with cinacalcet. The estimated difference in proportions of patients achieving reduction in PTH concentrations of >30% between the 198 of 343 patients (57.7%) randomized to receive cinacalcet and the 232 of 340 patients (68.2%) randomized to receive etelcalcetide was -10.5% (P for noninferiority, <0.001; P for superiority, 0.004). Additionally, 178 patients (52.4%) randomized to etelcalcetide achieved >50% reduction in PTH concentrations, compared with 138 patients (40.2%) randomized to cinacalcet (P=0.001).


Block GA, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017 Jan 10;317(2):156-64.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.